Global Hyperimmune Globulin Injection Market Growth 2025-2031
Description
The global Hyperimmune Globulin Injection market size is predicted to grow from US$ 2283 million in 2025 to US$ 3362 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.
Hyperimmune Globulin is a highly concentrated immunoglobulin containing high levels of specific antibodies used for passive immunotherapy. It is usually extracted from the plasma of recovered patients who have been infected with a specific pathogen, so these people have produced high levels of antibodies against the pathogen.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
LP Information, Inc. (LPI) ' newest research report, the “Hyperimmune Globulin Injection Industry Forecast” looks at past sales and reviews total world Hyperimmune Globulin Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Hyperimmune Globulin Injection sales for 2025 through 2031. With Hyperimmune Globulin Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hyperimmune Globulin Injection industry.
This Insight Report provides a comprehensive analysis of the global Hyperimmune Globulin Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hyperimmune Globulin Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hyperimmune Globulin Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hyperimmune Globulin Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hyperimmune Globulin Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Hyperimmune Globulin Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Hepatitis B Immuneglobulins
Rabies Immuneglobulins
Tetanus Toxin Immuneglobulins
Rho(D) Immune Globulin
Cytomegalovirus Immune Globulin
Varicella-Zoster Immune Globulin
Others
Segmentation by Application:
Government Institution
Private Sector
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL Behring
Grifols
Biotest
Kedrion
Emergent
Kamada
CNBG
Hualan Bio
Shanghai RAAS
CBPO
Sichuan Yuanda Shuyang
ADMA Biologics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hyperimmune Globulin Injection market?
What factors are driving Hyperimmune Globulin Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hyperimmune Globulin Injection market opportunities vary by end market size?
How does Hyperimmune Globulin Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Hyperimmune Globulin is a highly concentrated immunoglobulin containing high levels of specific antibodies used for passive immunotherapy. It is usually extracted from the plasma of recovered patients who have been infected with a specific pathogen, so these people have produced high levels of antibodies against the pathogen.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
LP Information, Inc. (LPI) ' newest research report, the “Hyperimmune Globulin Injection Industry Forecast” looks at past sales and reviews total world Hyperimmune Globulin Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Hyperimmune Globulin Injection sales for 2025 through 2031. With Hyperimmune Globulin Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hyperimmune Globulin Injection industry.
This Insight Report provides a comprehensive analysis of the global Hyperimmune Globulin Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hyperimmune Globulin Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hyperimmune Globulin Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hyperimmune Globulin Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hyperimmune Globulin Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Hyperimmune Globulin Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Hepatitis B Immuneglobulins
Rabies Immuneglobulins
Tetanus Toxin Immuneglobulins
Rho(D) Immune Globulin
Cytomegalovirus Immune Globulin
Varicella-Zoster Immune Globulin
Others
Segmentation by Application:
Government Institution
Private Sector
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL Behring
Grifols
Biotest
Kedrion
Emergent
Kamada
CNBG
Hualan Bio
Shanghai RAAS
CBPO
Sichuan Yuanda Shuyang
ADMA Biologics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hyperimmune Globulin Injection market?
What factors are driving Hyperimmune Globulin Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hyperimmune Globulin Injection market opportunities vary by end market size?
How does Hyperimmune Globulin Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
123 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Hyperimmune Globulin Injection by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Hyperimmune Globulin Injection by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
